Literature DB >> 32189545

Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count.

Isolde Summerer1, Claudia Haferlach1, Manja Meggendorfer1, Wolfgang Kern1, Torsten Haferlach1, Anna Stengel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32189545     DOI： 10.1080/10428194.2020.1737689

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

Review 1.  The International Consensus Classification of acute myeloid leukemia.

Authors:  Olga K Weinberg; Anna Porwit; Attilio Orazi; Robert P Hasserjian; Kathryn Foucar; Eric J Duncavage; Daniel A Arber
Journal:  Virchows Arch       Date:  2022-10-20       Impact factor: 4.535

2.  Clinical and Genomic Profiles of Korean Patients with MECOM Rearrangement and the t(3;21)(q26.2;q22.1) Translocation.

Authors:  Jikyo Lee; Sung Min Kim; Soonok Kim; Jiwon Yun; Dajeong Jeong; Young Eun Lee; Eun-Youn Roh; Dong Soon Lee
Journal:  Ann Lab Med       Date:  2022-09-01       Impact factor: 4.941

Review 3.  EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.

Authors:  Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-03-22       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.